A practical reference on WADA Prohibited List: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-01 and is reviewed periodically as new material appears.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
== Function == This protein is expressed largely in cells possessing a regulated secretory pathway, such as endocrine/neuroendocrine cells and neurons. The intact proSAAS protein, as well as the carboxyy-terminal peptide containing the inhibitory hexapeptide LLRVKR, functions as an inhibitor of prohormone convertase 1/3, which accomplishes the initial proteolytic cleavage of peptide precursors. ProSAAS is further processed at the N- and C-termini into multiple short peptides, leaving the central segment intact. This central, unprocessed portion of the protein may function as a neural- and endocrine-specific chaperone due to its potent ability to block the aggregation of beta amyloid and alpha synuclein in vitro, and to block oligomer cytotoxicity in cells. Recent data show that nigral proSAAS expression blocks the deterioration of the striatonigral pathway in a synuclein rat model of Parkinson's disease. ProSAAS also oligomerizes and undergoes liquid-liquid phase separation. Differential expression of this gene may be associated with obesity.
Evidence from the study of bone microanatomy of Neanderthal remains from Sesselfelsgrotte (Germany), indicative of an overall similar growth trajectory of Neanderthals and modern humans during their early life, is presented by Miszkiewicz et al. (2026), who also report the presence of probably pathological interglobular dentin in the studied fossil material that might be evidence of a metabolic bone disease. Zollikofer et al. (2026) compare the morphology of Neanderthal pelves from Sima de las Palomas (Spain) and Dederiyeh Cave (Syria) with those of modern humans, reporting evidence of morphological similarities of pelvic regions associated with childbirth, as well as evidence of differences in pelvic regions associated with locomotion. Sorrentino et al. (2026) report evidence of presence of overall more robust calcaneus in Neanderthals compared to modern humans, with the closest similarity to calcanei of highly mobile, unshod modern human groups. Verheijen et al. (2026) study evidence of Neanderthal activity in faunal remains from the Lehringen site (Germany), reporting evidence of defleshing of a straight-tusked elephant when its carcass was in fresh state and evidence of butchery of a beaver, bear and aurochs. Evidence indicating that exploitation of shellfish by Neanderthals occupying the Cave of Los Aviones (Spain) happened primarily during the colder months of the year is presented by García-Escárzaga et al. (2026).
Instantaneous – All 12 links "are realized in one and the same moment". Prolonged – The interdependence and causal relationship of dharmas is seen as arising at different times (across three lifetimes). Serial – The causal relationship of the twelve links arising and ceasing in a continuous series of mind moments.
Sources: en.wikipedia.org
Generally, when reactions take place in the liquid and solid phases the change in volume due to reaction is not significant enough that it needs to be taken into account. Reactions in the gas phase often have significant changes in volume and in these cases one should use these modified equations.
=== Bone mineral density === Bone mineral density (BMD) is a measure commonly used to quantify bone health. A lower BMD value indicates an increased risk of an osteoporosis or a fracture. There is a large range of factors influencing BMD. Protein consumption has shown to be beneficial for bone density by providing amino acid substrates necessary for bone matrix formation. It is also thought that blood concentration of the bone formation stimulant, Insulin-like Growth Factor-I (IGF-I), is increased from high protein consumption and parathyroid hormone (PTH), a bone resorption stimulant, is decreased. Although protein has shown to be beneficial for increasing bone mass, or bone mineral density, there is no significant association between protein intake and fracture incidence. In other words, a low BMD can be predictive of osteoporosis and increased fracture risk, but a higher BMD does not necessarily mean better bone health. High BMD is also correlated with other health issues. For example, a higher BMD has also been associated with increased risk of breast cancer.
In engineering, the elasticity of a material is quantified by the elastic modulus such as the Young's modulus, bulk modulus or shear modulus which measure the amount of stress needed to achieve a unit of strain; a higher modulus indicates that the material is harder to deform. The SI unit of this modulus is the pascal (Pa). The material's elastic limit or yield strength is the maximum stress that can arise before the onset of plastic deformation. Its SI unit is also the pascal (Pa).
=== 2008–2009: Beginnings === Riff Raff started rapping in 2005, making homemade CDs of his rapping over other artists' beats, and passing them out at various malls in the Greater Houston Area including Katy Mills Mall. He credited his early influences being Texas veteran rappers Devin the Dude and Paul Wall. Riff Raff took advantage of social media on Myspace, YouTube and WorldStarHipHop in late 2008, releasing songs, freestyle-videos, and sketch clips, which showcased his talent as slapstick and performance art. He did this with the help of his first talent manager, DB da Boss, whose studio provided recording and video services. DB spoke with LA Weekly about the rapper, saying "He was very driven, very ambitious. You couldn't deny his work ethic", going on to say, "Underneath that shell is a very intelligent man." He looked up to Northside Houston rappers from label Swishahouse, who were blowing up around that time, including Paul Wall, Chamillionaire and Slim Thug. He began doing his hair up in braids popular among "Northsiders" like Slim Thug and shopping for bling at TV Jewelry, a store co-owned by Paul Wall and charismatic Vietnamese immigrant "TV" Johnny Dang, from whom Riff Raff also purchased gold grills. Like many other artists from Houston, Riff Raff also spent much of his time selling CDs at colleges and malls, occasionally alongside other local talent such at Fat Tony and Freestyle Bully. In an effort to get on television he went on many auditions, including for a part in a peanut butter commercial intended for a teenager.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.